Fact CheckerSign in

NCT04289402Active, not recruiting

Individualized Brain Stimulation to Improve Mobility in Alzheimer's Disease

Modulating Brain Activity to Improve Cognitive-motor Function in Alzheimer's Disease

Source: ClinicalTrials.gov · Last updated 27 Apr 2026

Brief summary (registry, in English)

The objective of this study is to conduct a pilot, randomized sham-controlled trials to determine the feasibility and effects of a 10-session personalized tDCS intervention targeting the left dorsolateral prefrontal cortex on cognitive function, dual task standing and walking, and other metrics of mobility in 24 older adults with mild AD living in supportive housing.

Status (registry)
Active, not recruiting
Study type
Interventional
Enrollment
11 (actual)
First submitted
13 Feb 2020
Start date
Jan 2020
Primary completion date
Jan 2027
Lead sponsor
Hebrew SeniorLife
NCT number
NCT04289402

What you commit to

  • Study type: Interventional
  • Participants enrolled: 11
  • From Jan 2020 to the primary completion date, Jan 2027
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • A clinical history of stroke, Parkinson's disease or parkinsonian symptoms, multiple sclerosis, normal pressure hydrocephalus, or other neurological conditions outside of mild AD.
  • Use of antipsychotics, anti-seizure, benzodiazepines, or other neuroactive medications
  • Any report of physician-diagnosis of schizophrenia, bipolar disorder, or other psychiatric illness
  • Contraindications to MRI or tDCS, including reported seizure within the past two years, use of neuropsychological-active drugs, the risk of metal objects anywhere in the body, self-reported presence of specific implanted medical devices (e.g., deep brain stimulator, medication infusion pump, cochlear implant, pacemakers, etc.), or the presence of any active dermatological condition, such as eczema, on the scalp

Other

  • Inability to secure informant participation
  • Unwillingness to cooperate or participate in the study protocol
  • An inability to ambulate without the assistance of another person (canes or walkers allowed)
  • Any report of severe lower-extremity arthritis or physician-diagnosis of peripheral neuropathy
  • Severe depression defined by a Center for Epidemiologic Studies Depression scale score greater than 16

Who the study is looking for

  • Men and women aged 65 and older living within supportive housing facilities
  • Mild Alzheimer's disease (AD) defined by the combination of 1) at least mild cognitive impairment defined as a modified TICS score of ≤ 34, 2) informant-report of Instrumental Activities of Daily Living impairment as defined as a score of ≥ 6 on the NACC Functional Activities Questionnaire, and 3) a Clinical Dementia Rating score of 1.

Age in the registry: 65 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Hebrew Rehabilitation Center
Coordinator of this site? Confirm its status
RoslindaleUnited StatesUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.